Nasus Pharma (NSRX) Non-Current Deffered Revenue (2024)
Nasus Pharma (NSRX) reported Non-Current Deffered Revenue of $260000.0 for Q4 2024.
Nasus Pharma (NSRX) Non-Current Deffered Revenue (2024) Analysis & Trends
Nasus Pharma has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $260000.0 in Q4 2024.
- For the quarter ending Q4 2024, Non-Current Deffered Revenue changed N/A year-over-year to $260000.0; the trailing twelve-month figure through Dec 2024 stood at $260000.0 (changed N/A YoY), and the FY2024 full-year result was $260000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2024 stood at $260000.0.
- The five-year high for Non-Current Deffered Revenue was $260000.0 in Q4 2024, with the low at $260000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 260,000.00 |